Login / Signup

Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.

Mitsuru WatanabeYuri NakamuraZuzanna MichalakNoriko IsobeChristian BarroDavid LeppertTakuya MatsushitaFumie HayashiRyo YamasakiJens KuhleJun-Ichi Kira
Published in: Neurology (2019)
sGFAP and sNfL are likely to be good biomarkers of disease activity and disability, and the sGFAP/sNfL quotient at relapse is a potential diagnostic marker for NMOSD.
Keyphrases
  • disease activity
  • systemic lupus erythematosus
  • rheumatoid arthritis
  • rheumatoid arthritis patients
  • ankylosing spondylitis
  • multiple sclerosis
  • juvenile idiopathic arthritis
  • cerebrospinal fluid
  • free survival